Observed arrival · 2026-09-19
PeptideBlog Grades the Evidence Instead of the Hype
A peptide reference that separates approved uses, human trials, animal studies, anecdotes, and disputed claims.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Readers evaluating peptide claims and evidence
- Worth noticing
- Its E1–E5/Q scale distinguishes approved labels, human trials, preclinical work, community reports, and disputed claims.
Field notes
Entries distinguish approved products from experimental or off-label uses, including examples such as Scenesse, Vyleesi, and Pitocin. The site also records negative or limited findings: its DSIP entry describes modest effects in older trials, while its oxytocin entry cites a 2026 meta-analysis of 42 randomized controlled trials with an overall effect close to zero for the described intranasal use. No products, vendor links, or affiliate deals are presented.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue